Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Contingent responses Clear all
Terminated Not applicable Interventional Results available

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

NCT00868751
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Interventions
tocilizumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin QD (once daily) for 7 days
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Cypress, California • DeLand, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Brain Biomarkers of Response to Treatment for Apraxia of Speech

NCT02046941
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
Speech Production Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
View directory record Official record
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 18, 2026, 1:19 AM EDT
Completed No phase listed Observational

The Stress-Hormone System in Alcohol-Dependent Subjects

NCT00536146
View directory record Official record
Conditions
Alcoholism
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 60 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

NCT03062878
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions
Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
Other
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

NCT02287558
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Interventions
Pomalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 18, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive BCI-controlled Assistive Devices

NCT05183152
View directory record Official record
Conditions
Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Interventions
NMES Feedback, Visual Feedback, TESS
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Scotoma Perimetry Oculomotor Training

NCT05456581
View directory record Official record
Conditions
Macular Degeneration, Central Visual Impairment
Interventions
'Scotoma awareness' Training, Control Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

NCT01489956
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes

NCT00960778
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol), denicotinized cigarettes (Quest 3 cigarettes)
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional

The Neurobiology of Approach Avoidance Training in Depression

NCT02330744
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Approach-positive AAT, Control AAT
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 18, 2026, 1:19 AM EDT
Recruiting Phase 4 Interventional

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079
View directory record Official record
Conditions
Crohn Disease
Interventions
Tirzepatide, Mediterranean diet
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Terminated Not applicable Interventional

Understanding the Pathophysiology of Migraine Pain

NCT03026101
View directory record Official record
Conditions
Migraine Disorders, Migraine, Classic, Migraine Without Aura
Interventions
Nitroglycerin
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Investigating the Impact of JASPER Behavioral Therapy in Children With Down Syndrome

NCT05638412
View directory record Official record
Conditions
Down Syndrome
Interventions
JASPER, Psychoeducational Curriculum
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
36 Months to 90 Months
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence

NCT02602795
View directory record Official record
Conditions
Opiate Dependence, Sexually Transmitted Diseases, HIV
Interventions
Acceptance and Commitment Therapy, Information Motivation Behavioral Model
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Olaparib
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Azusa, California • Los Angeles, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project

NCT03799341
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Phase 3 Interventional

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

NCT00002827
View directory record Official record
Conditions
Cardiac Toxicity, Lymphoma
Interventions
bleomycin sulfate, filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 18, 2026, 1:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Physiological Responses in Tobacco Chippers

NCT01237834
View directory record Official record
Conditions
Smoking, Stress
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
25 Years to 55 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 18, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Chronic Alcohol, Stress Inflammatory Response and Relapse Risk

NCT02193204
View directory record Official record
Conditions
Alcohol Dependence, Depressive Symptomatology
Interventions
Personal Stress Imagery, Neutral Imagery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 18, 2026, 1:19 AM EDT